478 related articles for article (PubMed ID: 30348224)
21. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
22. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Moehler M; Dvorkin M; Boku N; Özgüroğlu M; Ryu MH; Muntean AS; Lonardi S; Nechaeva M; Bragagnoli AC; Coşkun HS; Cubillo Gracian A; Takano T; Wong R; Safran H; Vaccaro GM; Wainberg ZA; Silver MR; Xiong H; Hong J; Taieb J; Bang YJ
J Clin Oncol; 2021 Mar; 39(9):966-977. PubMed ID: 33197226
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
24. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JCH; Ishii H; Garassino M; de Marinis F; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Xiong H; Bajars M; Ruisi M; Barlesi F
J Thorac Oncol; 2021 Aug; 16(8):1369-1378. PubMed ID: 33845211
[TBL] [Abstract][Full Text] [Related]
25. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; Georges S; Ellers-Lenz B; Shah P; Güzel G; Nghiem P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301810
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
27. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
29. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
[TBL] [Abstract][Full Text] [Related]
30. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
31. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
[TBL] [Abstract][Full Text] [Related]
32. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF; Burton C; Radford J; Miall F; Townsend W; Santoro A; Zinzani PL; Lewis D; Fowst C; Brar S; Huang B; Thall A; Collins GP
Blood Adv; 2021 Sep; 5(17):3387-3396. PubMed ID: 34477818
[TBL] [Abstract][Full Text] [Related]
33. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
[TBL] [Abstract][Full Text] [Related]
34. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
35. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse J
Liver Cancer; 2021 Jun; 10(3):249-259. PubMed ID: 34239811
[TBL] [Abstract][Full Text] [Related]
36. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
37. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
[TBL] [Abstract][Full Text] [Related]
38. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
39. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
Colevas AD; Bahleda R; Braiteh F; Balmanoukian A; Brana I; Chau NG; Sarkar I; Molinero L; Grossman W; Kabbinavar F; Fassò M; O'Hear C; Powderly J
Ann Oncol; 2018 Nov; 29(11):2247-2253. PubMed ID: 30219915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]